Skip to main content
Clinical Trials/JPRN-UMIN000004224
JPRN-UMIN000004224
Recruiting
Phase 4

Comparison study for ocular hypotensive effect of switching from Travoprost 0.004% and Timolol maleate(Timoptol®-XE ophthalmic Solution 0.5%) ,Travoprost 0.004% and long-acting 2% Carteolol to a conbined opthalmic solution Travoprost 0.004%/Timolol 0.5% - Comparison study for ocular hypotensive effect of switching from Travoprost 0.004% and Timolol maleate,Travoprost 0.004% and long-acting 2% Carteolol to a conbined opthalmic solution Travoprost 0.004%/Timolol 0.5%

Department of Ophthalmology Yokohama City University Hospital0 sites30 target enrollmentSeptember 17, 2010
ConditionsGlaucoma

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Glaucoma
Sponsor
Department of Ophthalmology Yokohama City University Hospital
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 17, 2010
End Date
September 1, 2013
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Ophthalmology Yokohama City University Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1Patient, who has been managed due to chronic or replace uvetis, sceritis and herpes cornea. 2\.Patient, who has been managed by traumatic diseases,ocular surgery,laser operation within 3 months. 3\.Patinet, who is not available to measure by Aplanation tonomater. 4\.Patinet, who has irritation for PG eye solution, related PG eye solution and Benzalkonium chloride(BAC). 5\.Patient, who is severe Alzheimer. 6\.Patinet, who has been managed by oral CAI or steroid eye solution. 7\.Patinet, who has been applied other IOP reductive drug.

Outcomes

Primary Outcomes

Not specified

Similar Trials